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Summary 1 
Objective Thyroid hormone suppression therapy has been widely used in the treatment 2 of thyroid cancer, but concerns have been raised about the cardiovascular risks of this 3 treatment. The objective of this study was to evaluate long-term cardiovascular morbidity 4 and mortality in patients treated for differentiated thyroid cancer (DTC) and to assess the 5 effect of TSH suppression and radioiodine (RAI) treatment on the cardiovascular outcome. 6 
Design Retrospective cohort study 7 
Patients and Measurements Patients (n=901) treated for DTC between 1981-2002 at 8 two Finnish University hospitals were compared with a randomly chosen reference group 9 (n=4485) matched for age, gender and the place of residence. Kaplan-Meier and Cox 10 regression analyses were used to estimate the risk of morbidity or death due to different 11 cardiovascular diseases (CVD) after the diagnosis of DTC.  12 
Results Morbidity due to any CVD (hazard ratio [HR] 1.16, 95% confidence interval [CI] 13 1.05-1.28) and due to all arrhythmias (HR 1.25, CI 1.06-1.48) and atrial fibrillation (HR 14 1.29, CI 1.06-1.48) was more frequent in the DTC patients than in the controls.  The 15 increased cardiovascular morbidity was confined to patients with a mean TSH level below 16 0.1 mU/l (HR 1.27, CI 1.03-1.58), and to those treated with RAI (HR 1.18, CI 1.06-1.32). 17 Cardiovascular mortality, however, was lower among the patients than the controls (HR 18 0.73, CI 0.58-0.92), due to a lower mortality from coronary artery disease.  19 
Conclusions DTC patients have an increased CVD morbidity, which is mostly accountable 20 to atrial fibrillation, and to TSH suppression below 0.1 mU/l.  21 
Key words Cardiovascular Diseases, Atrial Fibrillation, Thyroid Neoplasms, Thyroid 22 Hormones, Iodine Radioisotopes, Follow-Up Studies, Mortality 23 
4 
Introduction 24 
Differentiated thyroid cancer (DTC) includes papillary and follicular thyroid cancer and 25 represents over 90 % of all thyroid cancers detected (1). The incidence of thyroid cancer 26 has increased over the past few decades; in the US the incidence has nearly tripled 27 between the years 1975-2009 (2,3). The increasing incidence of thyroid cancer has been 28 explained by early diagnosis leading to a growing number of small papillary thyroid 29 cancers, which have an excellent prognosis (2,3). The increased use of neck area imaging 30 may reveal incidental thyroid cancers with no effect on survival (4,5). Despite the 31 increased incidence, mortality from thyroid cancer has remained stable (2).  32  Diagnosis of small low-risk tumours may expose the patients to aggressive cancer 33 treatment, which may have unfavourable long-term effects (3). Thyroid hormone 34 suppression therapy (THST) by levothyroxine has been traditionally used as a treatment 35 of thyroid cancer to improve the outcome, but recently the necessity and safety of this 36 treatment in low-risk patients has been questioned (6,7). There are concerns about the 37 long-term cardiovascular effects of THST-induced iatrogenic thyrotoxicosis (6,7), as the 38 risks of endogenous hyperthyroidism are well known (8).  39  Increased cardiovascular mortality and an increased risk of atrial fibrillation (AF) have 40 been reported among DTC patients (9-12). An association between a low TSH level and an 41 increased risk of cardiovascular mortality has been found in patients treated for DTC (9). 42 THST has been reported to increase myocardial strain, left ventricular mass, and diastolic 43 dysfunction, to impair arterial elasticity, and to induce prothrombotic changes in DTC 44 patients (13-16). The most recent guidelines on DTC recommend weighing the potential 45 benefits of THST against the possible harms of stringent TSH suppression (17-19). For the 46 
5 
time being, the appropriate degree of TSH suppression remains unsettled, and there are 47 discrepancies between different guidelines (17-19).  48  The aim of this study was to evaluate the long-term cardiovascular morbidity and 49 mortality in DTC patients. The secondary aim was to assess the effect of the TSH 50 suppression level and radioiodine (RAI) treatment on the cardiovascular outcome of the 51 patients.  52 
Materials and Methods 53 
In this retrospective study, all the patients treated for DTC between 1981 and 2002 at two 54 Finnish University Hospitals (Tampere and Oulu University Hospital, responsible for the 55 specialized health care of 16 % of the Finnish population) were included. Details of this 56 cohort have been recently described in a study analyzing the risk of second cancer after 57 the treatment of DTC (20). In short, this study included 920 consecutive patients, most of 58 whom had a total thyroidectomy (78 %) and were subsequently treated with RAI (81 %). 59 Of the patients, 493 were treated at Tampere University Hospital and 427 at Oulu 60 University Hospital. Nineteen patients and their corresponding controls were excluded 61 because of missing information, errors in the identification numbers, or limitations 62 regarding data release. For each patient, five controls were chosen from the Population 63 Register Center of Finland, individually matched for age, gender, and the place of 64 residence. Controls diagnosed with thyroid cancer (n=12) during the follow-up were 65 excluded.  66  Follow-up of the patients started on the date of DTC diagnosis and on the same date 67 for the corresponding controls. The follow-up regarding cardiovascular morbidity ended 68 on the date of the first cardiovascular disease (CVD) -associated outpatient visit or 69 
6 
hospitalization, date of death, date of emigration, or the common closing date 70 (31.12.2014), whichever occurred first. Information regarding the treatment of DTC 71 patients was collected from the medical records of the two participating hospitals. 72  Cardiovascular morbidity was evaluated on the basis of hospital visits at any Finnish 73 hospital due to CVD during the follow-up. Information on CVD–associated hospital visits 74 was obtained from the nationwide Hospital Discharge Registry (HILMO), which is 75 maintained by the National Institute of Health and Welfare (THL). This registry includes 76 the inpatient hospital admissions of all Finnish residents since 1969 and the outpatient 77 hospital visits since 1996. The hospitalization or outpatient visit was included in the 78 analyses, if the primary or one of the two first secondary diagnoses at discharge was a 79 cardiovascular disease, according to the International Classification of Diseases (ICD). 80 Between 1969 and 1986 the ICD-8 codes 400-458 were included, between 1987 and 1995 81 the ICD-9 codes 400-459, and from the year 1996 on, the ICD-10 codes I10-99 were 82 included.  83  The CVD diagnoses were categorized into nine main groups (21): hypertension, 84 coronary artery disease, diseases of the pulmonary circulation, arrhythmias, heart failure, 85 cerebrovascular disease, diseases of the arteries and veins, valvular diseases and cardio-86 myopathies. In the group of arrhythmias, AF was also studied separately. First, morbidity 87 due to any CVD was evaluated. Then, morbidity because of the different CVD subgroups 88 was analysed separately, regardless of any morbidity due to other CVD diagnoses. Only 89 the first hospitalization or outpatient visit due to a given CVD disease was included in the 90 analysis.  91  Data on the causes and time of death were obtained from Statistics Finland, and 92 information on emigration from the Population Registration Centre. The underlying cause 93 of death was used in the mortality analyses. Information from the separate registers was 94 
7 
linked together by using the unique personal identification number assigned to all Finnish 95 residents. 96  The ethics committee of the Pirkanmaa Hospital District approved the study protocol 97 (study number R15144).  The National Institute of Health and Welfare, Statistics Finland, 98 the Population Register Centre, and the University Hospitals yielded permission for the 99 use of data from their registers. The Declaration of Helsinki was obeyed during the study. 100 
Statistical analysis 101 
The statistical analyses were performed with the IBM SPSS Statistics version 24.0 (IBM 102 Corp. Released 2016). Unpaired t test was used to compare the mean age during the first 103 hospital visit due to a CVD between the patients and the controls. Mann-Whitney U test 104 was used to compare the median follow-up times. Kruskall Wallis test was used to 105 compare the age and the cumulative dose of RAI between the three TSH groups. The 106 cumulative rate of CVD-associated hospital visits, overall mortality and cardiovascular 107 mortality were compared between the patients and the controls by using Kaplan-Meier 108 curves and the log-rank test. 109  The data on all the TSH measurements performed during the study period were 110 available on the patients treated at Tampere University Hospital. The association between 111 the TSH level and the CVD outcome was analyzed by using a geometric mean (9) of all 112 available TSH measurements after the diagnosis of DTC. The geometric mean TSH level 113 was categorized into three groups, according to the American Thyroid Association 114 recommendation (below 0.1 mU/l, 0.1 to 0.5 mU/l, and above 0.5 mU/l). TSH values 115 below the detection limit were given the numeric value of the detection limit of the TSH 116 
8 
method (for example <0.01 mU/l was assumed as 0.01 mU/l). The doses of RAI 117 treatments were obtained from the medical records of both hospitals. 118  Three different kinds of Cox regression analyses were performed. The first analysis 119 included all the DTC patients and controls, and the hazard ratios (HR) and 95% 120 confidence intervals (95% CI) were estimated for morbidity and mortality due to different 121 CVDs after the diagnosis of DTC. Prevalent CVD was used as a covariate in the analysis to 122 adjust for CVD morbidity before the start of the follow-up.  123  In the second analysis, hazard ratios for morbidity due to any CVD were determined in 124 the following subgroups of patients and their corresponding controls: age (< 40 years, 40-125 
59 years and ≥ 60 years), gender, geometric mean TSH level during follow-up (<0.1 mU/l, 126 0.1 to 0.5 mU/l and >0.5 mU/l) and RAI treatment status (yes, no).  127  The third analysis included only the DTC patients and it was performed to evaluate the 128 effect of the different patient- and treatment-associated factors on the risk of CVD 129 morbidity. The covariates used were gender, age, prevalent CVD, TSH level (per 1 mU/l 130 increase) and cumulative RAI dose (per 100 mCi increase). This analysis included only the 131 patients treated at Tampere University Hospital, because the TSH data was available only 132 regarding these patients. 133  The analyses were repeated with a subdistribution hazards model, in which the 134 competing event of death in the analysis of cardiovascular morbidity, and the competing 135 event of non-cardiovascular death in the analysis of cardiovascular mortality were taken 136 into account. The subdistribution hazards ratios were calculated with the statistical 137 software Stata for Windows version 13.0 (StataCorp, College Station, TX, USA).  138 
9 
Results 139 
A total of 901 DTC patients and 4485 controls were included in the study, and 81% of 140 them (n=733) were female (Table 1). The mean age at the time of DTC diagnosis was 48 141 (standard deviation [SD] 16) years. Most of the patients 79% (n=709) had papillary 142 cancer, 11% (n=97) had follicular cancer, and 10% (n=95) had a follicular variant of 143 papillary thyroid cancer. The number of the study subjects and their CVD-associated 144 hospital visits are shown in Figure 1. The median follow-up time was 18.8 (interquartile 145 range [IQR] 14.4-23.5) years in the DTC patients and 19.0 (IQR 15.1-23.4) years in the 146 controls (p=0.391). A cancer recurrence was recorded  in 15% (n=134) of the patients. 147 During the follow-up 28% of the patients (n=250) and 28% of the controls (n=1237) died. 148  Morbidity due to any CVD (HR 1.16, 95% CI 1.05-1.28) was increased among the DTC 149 patients compared with the controls (Figure 2, Panel a and Table 2). The results did not 150 change when the subjects with a prevalent CVD were excluded or when the 151 subdistribution hazards model was used. During the follow-up, 53% (n=478) of the 152 patients and 48% (n=2134) of the controls were treated for a CVD. The mean age during 153 the first treatment due to any CVD was 63.0 (SD 13.8) years in the patients and 64.7 (SD 154 14.2) years in the controls (p=0.014). The median time from the beginning of the follow-155 up to the first treatment due to any CVD was 9.0 (IQR 4.2-14.8) years in the patients and 156 9.4 (IQR 4.0-15.3) years in the controls (p=0.512). 157  When the different CVDs were studied separately, the risk of all arrhythmias (HR 1.16, 158 95% CI 1.06-1.48) and AF (HR 1.29, 95% CI 1.06-1.57) was increased among the DTC 159 patients, compared to the controls (Figure 2, Panel b-c and Table 2). The results did not 160 change when the subjects with prevalent arrhythmias or prevalent AF were excluded, or 161 when the subdistribution hazards model was used. During the follow-up, 13% of the 162 
10 
patients and 11% of the controls were treated for AF. The mean age of the DTC patients 163 during the first treatment for AF was 70.3 (SD 12.0) years and 73.1 (SD 11.2) years for the 164 controls (p=0.015). The median time from the beginning of the follow-up to the first 165 treatment due to AF was 13.1 (IQR 7.3-16.6) years for the patients and 13.1 (IQR 7.7-18.8) 166 years for the controls (p=0.440). 167  In the subgroup analysis, morbidity due to any CVD was increased in patients under 40 168 years of age  (HR 1.27, 95% CI 1.00-1.60) and also in patients aged 40 to 59 years (HR 169 1.23, 95% CI 1.07-1.43), compared with the corresponding controls. The risk tended to 170 increase also in patients aged 60 or over (HR 1.17, 95% CI 0.99-1.38). Female patients had 171 an increased risk of hospital treatments due to any CVD compared with their controls (HR 172 1.14, 95% 1.02-1.28).  173  There was no difference in the overall mortality (HR 0.98, 95% CI 0.85-1.12) between 174 the DTC patients and the controls (Figure 3, Panel). Cardiovascular mortality, however, 175 was lower among the patients than the controls (HR 0.73, 95% CI 0.58-0.92), which was 176 accountable to a lower mortality from coronary artery disease among the patients (HR 177 0.69, 95% CI 0.50-0.95) (Figure 3, Panel b, Table 3, supplements). The result remained 178 unchanged when the subdistribution hazards model was used. 179  AF was recorded as an underlying cause, a contributory cause or the direct cause of 180 death in 5% (n=13) of the patients and 6% (n=77) of the controls (p=0.535). The most 181 common CVD cause of death was coronary artery disease, which was the underlying cause 182 of death in 17% (n=42) of the patients and 25% (n=315) of the controls. Of the DTC 183 patients, 7.7% (n=69) died of the thyroid cancer. Among the deceased DTC patients, 28% 184 (n=69) died of the thyroid cancer, 32% (n=81) of a CVD and 40% (n=100) from other 185 causes. In the control group, 43% (n=533) died of a CVD and 57% (n=704) from other 186 causes.  187 
11 
 Altogether 11292 TSH measurements from 469 patients were available for the 188 analyses. Of the TSH measurements, 5068 (45%) were below the detection limit. The 189 median number of TSH measurements per patient during the follow-up was 23 190 (interquartile range [IQR] 14-33).  191  The patients in the different TSH groups differed regarding the age at DTC diagnosis 192 (p<0.001). The median age of patients with a geometric mean TSH level below 0.1 mU/l 193 was 44.6 (IQR 34.7-52.6) years vs. 51.4 (IQR 40.4-67.5) years in the patients with TSH 194 between 0.1 and 0.5 mU/l, and 60.1 (IQR 49.2-70.2) years in the patients with TSH above 195 0.5 mU/l. Also, the cumulative dose of RAI differed between the TSH groups (p=0.005). 196 Among patients who did not receive RAI a greater proportion (27%, n=36) had TSH above 197 0.5 mU/l compared with patients who received RAI (16%, n=53).    198  In the subgroup analysis, the patients with a geometric mean TSH level under 0.1 mU/l 199 had an increased risk of CVD morbidity (HR 1.27, 95% CI 1.03-1.58), compared with the 200 corresponding controls (Figure 4, Panel a-c). The risk also tended to increase in patients 201 with a mean TSH > 0.5 mU/l (HR 1.31, 95 % CI 0.98-1.77), but not in those with a TSH 202 level between 0.1 and 0.5 mU/l (HR 1.04, 95 % CI 0.83-1.31). These results did not change 203 when the TSH values above 30 mU/l were excluded. 204  Of the DTC cohort, 81% (n=732) were treated with RAI ablation. The median 205 cumulative dose of RAI was 100 mCi (IQR 100-150 mCi). In the subgroup analysis, the 206 patients treated with RAI ablation had an increased risk of CVD morbidity (HR 1.18, 95% 207 CI 1.05-1.31) compared to the corresponding controls, contrary to the patients not treated 208 with RAI vs. their respective controls (HR 1.07, 95% CI 0.85-1.34) (Figure 4, panels c-d).  209  In the Cox regression analysis including only the patients, age (HR 1.05, 95% CI 1.04-210 1.06), male gender (HR 1.62, 95% CI 1.19-2.22) and a prevalent CVD at the time of DTC 211 diagnosis (1.68, 95% CI 1.25-2.24) predicted morbidity due to any CVD, whereas the TSH 212 
12 
level or the cumulative dose of RAI did not have a statistically significant effect on CVD 213 morbidity.  214 
Discussion 215 
To our knowledge, this is the largest study evaluating cardiovascular morbidity and 216 mortality among DTC patients with a long follow-up time. This study is also the first one 217 to report the risk of other cardiovascular diseases in addition to AF in DTC. We found that 218 the risk of hospital treatment due to any cardiovascular disease is increased among 219 patients treated for DTC, compared with age- and gender-matched control group. The 220 increased risk is mostly accountable to an increased risk of AF.  221  Based on previous studies, the survival rate of patients diagnosed with a DTC is 222 excellent (3). No difference in the all-cause mortality was found between the patients with 223 DTC, and the matched control group in the present study, either. Given the similar life 224 expectancy compared with the general population, the co-morbidities, the quality of life, 225 and the burden of the cancer treatments should be taken into account, in addition to the 226 risk of cancer recurrence. Studies on endogenous subclinical and clinical hyperthyroidism 227 indicate an increased risk of cardiovascular morbidity and mortality (8,21,22). Findings 228 from endogenous thyroid disease, however, cannot be generalised on thyroid cancer 229 patients, because endogenous and exogenous thyrotoxicosis are not entirely comparable 230 conditions, and they may impose different risks on the cardiovascular system (11,23).  231  Previous studies on DTC patients have reported an increased incidence of AF, but no 232 association between the TSH level and AF incidence, although such an association is 233 known to exist in endogenous hyperthyroidism (24,25). Abonowara et al. (11) found an 234 increased prevalence of AF among 136 thyroid cancer patients, but no correlation 235 
13 
between the level of TSH and the occurrence of AF. Klein Hesselink et al. (10)  also 236 reported an increased risk of AF among 518 DTC patients, but there was no association 237 between the TSH level and the risk of AF, whereas the cumulative dose of RAI was 238 associated with a slightly increased AF risk. No difference in the risk of AF was found in a 239 cohort of 771 thyroid cancer patients with suppressed (TSH ≤ 0.4 mU/l) versus those with 240 non-suppressed (> 0.4 mU/l) TSH concentrations (12).  In our study patients with a mean 241 TSH level below 0.1 mU/l had an increased CVD risk compared with the corresponding 242 controls. The risk tended to increase also in the patients with TSH above 0.5 mU/l, but the 243 difference was not statistically significant. Previously, a U-shaped relationship between 244 thyroid hormone concentrations and cardiovascular parameters has been reported in 245 DTC patients studied during exogenous thyrotoxicosis, euthyroidism and hypothyroidism, 246 both ends of the range showing similar effects on myocardial mechanical properties (13).  247  In contrast to our results indicating decreased cardiovascular mortality, Klein 248 Hesselink et al. in 2013 reported a significantly increased risk of cardiovascular and all-249 cause mortality in 524 DTC patients during an 8.5-year follow-up, and the risk was 250 independent of age, sex and cardiovascular risk factors (9). A low TSH level was 251 associated with increased cardiovascular mortality, but the cumulative RAI dose was not. 252 Other studies, however, do not indicate increased cardiovascular mortality in DTC 253 patients (26,27). Eustatia-Rutten et al. in 2006 found that the number of non-thyroid 254 cancer-related deaths in T1–3M0 DTC patients were lower compared with age- and sex-255 matched cohort of the general population (26). In our study, the cardiovascular mortality 256 was lower among the patients than controls. If a DTC patient dies of thyroid cancer, 257 he/she cannot reach the endpoint of a cardiovascular or another non-thyroid cancer-258 related death, which may underestimate the risk of cardiovascular death in the DTC 259 cohort (26). In this study cardiovascular mortality remained lower among the patients 260 
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than among the controls, when the competing event of non-cardiovascular death was 261 taken into account.  262  One explanation for the lower cardiovascular mortality among the DTC patients might 263 be the lifelong follow-up of DTC patients, during which cardiovascular risk factors may be 264 revealed and treated earlier, compared with the general population (26). Hypothyroidism 265 is related to hypercholesterolaemia, atherosclerosis and an increased risk of coronary 266 artery disease (28). In contrast to hypothyroidism, exogenous subclinical thyrotoxicosis 267 might have beneficial effects, protecting from coronary artery disease.  268  In our study, the death certificate data from Statistics Finland, and the underlying 269 cause of death was used for both the patients and the controls. In Finland the registration 270 of an underlying cause of death is mandatory. Also, the entry of diagnosis codes to HILMO 271 is mandatory when a patient is discharged from a hospital. Therefore, the high quality and 272 completeness of the data obtained from these nationwide registers are a significant 273 strength of this study. (29) Previous studies indicate that the validity of CVD diagnoses in 274 these registers is high (29,30).  275  However, the register-based study method has limitations. The HILMO register 276 includes only visits in the specialized health care system, which may underestimate the 277 incidence of non-severe cardiovascular diseases among both the patients and the controls. 278 Technical errors in the entry of CVD diagnosis codes or misdiagnosis of the CVDs are 279 possible. However, all the DTC diagnoses were confirmed when the information was 280 collected from the medical records of the hospitals. CVDs might have been diagnosed 281 more likely among the DTC patients, because of the lifelong follow-up of DTC, which could 282 overestimate the risk of CVD morbidity of the DTC patients.  283  A limitation is that we did not have information on cardiovascular risk factors, such as 284 smoking, diabetes, or body mass index. Also, we did not have information on the 285 
15 
prevalence of endogenous thyroid disorders among the controls, nor did we have 286 information on the use of levothyroxine or antithyroid drugs. Both hyperthyroidism and 287 hypothyroidism have been found to increase cardiovascular morbidity. Regardless of the 288 possibility of thyroid disorders among the control group, the risk of cardiovascular 289 morbidity was increased among the DTC patients.  290  Because of the retrospective study method, conclusions cannot be drawn about the 291 causality between DTC treatment and CVD morbidity, i.e., whether the increased 292 cardiovascular morbidity is due to the cancer or its treatment, or a shared risk factor for 293 DTC and cardiovascular morbidity.   294   In conclusion, we found that the survival rate of patients diagnosed with a DTC is 295 excellent, but the risk of cardiovascular diseases is increased among patients treated for 296 DTC, compared with age- and gender-matched controls. The increased risk is mostly 297 accountable to an increased risk of atrial fibrillation. The patients with a low mean TSH 298 level (<0.1 mU/l) have an increased risk of CVD. While the study rises concerns about the 299 long-term cardiovascular effects of THST-induced iatrogenic thyrotoxicosis, the optimal 300 level of TSH remains to be settled in future studies.   301 
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Figure legends 
Figure 1 The number of the study subjects and their hospital visits associated with 305 cardiovascular diseases. 306 
Figure 2 Cumulative morbidity due to all cardiovascular diseases, all arrhythmias and 307 atrial fibrillation in patients treated for differentiated thyroid cancer, compared with the 308 matched control group (log-rank test).  309 
Figure 3 All-cause mortality and cardiovascular mortality in the patients treated for 310 differentiated thyroid cancer, compared with the matched control group (log-rank test). 311 





Table 1. General information and follow-up times for the patients treated for differentiated thyroid cancer and the randomly chosen control groupa. Patients (n=901) Controls (n=4485) Age, mean (SD) 48.8 (15.9) 48.7 (15.8) Gender, female (%) 733 (81%) 3650 (81%) Follow-up time, years, median, (IQR) 18.8 (14.4-23.5) 19.0 (15.1-23.4) Pathology    PTCb 709 (79%) -    PTCb follicular variant 95 (11%) -    FTCc 97 (11%) - TSH leveld, mU/l, median, (IQR) 0.11 (0.05-0.35) -    below 0.1 mU/l 215 (46%) -    0.1 to 0.5 mU/l 165 (35%) -    above 0.5 mU/l 89 (19%) - RAIe treatment, GBq, median, (IQR) 3.7 (3.7-6.9) -    No RAI 169 (19%) -    below 3.7 GBq 522 (58%) -    above 3.7 GBq 210 (23%) - 
aThe patients and the controls were matched for age, gender and the place of residence. bPTC papillary thyroid cancer, cFTC follicular thyroid cancer dGeometric mean of all available TSH measurements after the diagnosis of thyroid cancer, available from 469 patients  eRAI radioiodine treament 
Table 2. Cardiovascular morbidity of patients treated for differentiated thyroid cancer (DTC) compared with a control group matched for age, gender and the place of residence.  Hospital visits Patients vs. controls Cardiovascular disease Patients  (n=901) Controls (n=4485) Hazard ratioa (CI) P value All cardiovascular    diseases 478 2134 1.16 (1.05-1.28) 0.004* Hypertension 210 914 1.16 (0.99-1.34) 0.060 All arrhythmias 170 693 1.25 (1.06-1.48) 0.008* Atrial fibrillation 120 485 1.29 (1.06-1.57) 0.013* Diseases of arteries       and veins 172 774 1.12 (0.95-1.32) 0.193 Coronary artery disease 145 786 0.94 (0.78-1.12) 0.457 Cerebrovascular    diseases 84 440 0.98 (0.78-1.24) 0.865 Heart failure 61 383 0.77 (0.59-1.01) 0.054 Valvular diseases and       cardiomyopathies 38 151 1.26 (0.88-1.79) 0.213 Diseases of pulmonary    arteries 24 83 1.48 (0.94-2.33) 0.091 
aAdjusted for prevalent cardiovascular morbidity prior to the diagnosis of DTC (Cox regression analysis)  *Statistically significant difference between the patients and the controls
Table 3. Mortality from different cardiovascular diseases in patients treated for differentiated thyroid cancer (DTC) compared with a control group matched for age, gender and the place of residence.  Deaths Patients vs. controls Cause of death Patients (n=901) Controls (n=4485) Hazard ratioa (CI) P value All deaths 250 1237 0.98 (0.85-1.12)        0.754 Cardiovascular deaths 81 533 0.73 (0.58-0.92)    0.008* Hypertension 5 12 1.93 (0.68-5.51)   0.219 All arrhythmias 4 13 1.52 (0.50-4.67)     0.463 Atrial fibrillation 3 12 1.24 (0.35-4.40)     0.740 Diseases of arteries    and veins 10 36 1.39 (0.69-2.79)      0.362 Coronary artery disease 42 315 0.69 (0.50-0.95)        0.023* Cerebrovascular     diseases 16 119 0.69 (0.41-1.16)     0.161 Heart failure 3 10 1.40 (0.38-5.11)    0.110 Valvular diseases and     cardiomyopathies 0 21 0.970 Diseases of pulmonary      arteries 1 4 1.29 (1.44-11.55)       0.820 
aAdjusted for prevalent cardiovascular morbidity prior to the diagnosis of DTC (Cox regression analysis)  *Statistically significant difference between the patients and the controls
